Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on September 5, 2023, Morgan Stanley maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-184873146-574748093df78c6bb088a35b.jpg "<div>403(b) vs. 401(k) Plans: What's the Difference?</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2173588208-8c8f22f916ad46719d9aff854e35bd97.jpg "Should You Work at a Boutique Investment Bank?")